Penny Stocks To Buy [Or Avoid] #2 Agile Therapeutics
Another one of the penny stocks that has been followed closely on PennyStocks.com is Agile Therapeutics (AGRX – Stock Report). The primary focus of the company is related to its hormonal contraceptive Twirla. It received a non-binding approval from the FDA some time ago.
AGRX stock has soared by as much as 40% over the past three weeks in anticipation of Twirla data that is going to be released on February 16. Investors could keep an eye on the development in this regard. The FDA previously denied the originally submitted New Drug Application in 2013. Agile resubmitted that in 2017. But it was again denied. The main reason according to the FDA was with regard to certain quality measurements in test methods. So this could be a pivotal time for Agile.
Since late last year, AGRX stock has been on the move. When we first started to follow the company closely, shares traded around $1. Obviously, since then the penny stock has gone on a monstrous run. But another bad report could be a huge hit for Agile. So I would think caution would be the prudent route for the time being. Regardless, a good result could be a huge win for the company as well. I wouldn’t be surprised to see volatility between here and there.
